Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 13/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 13/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 11/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081494 | 0.85 | MAPK14 (0.44) | MAPK14HTR7 | |
| SCHEMBL6081184 | 0.85 | MAPK14 (0.45) | KMT2AMAPK14HTR7MAPK1MEN1 | |
| SCHEMBL6081327 | 0.80 | MAPK14 (0.52) | MAPK14HTR7 | |
| SCHEMBL6082367 | 0.78 | MAPK14 (0.50) | MAPK14HTR7 | |
| SCHEMBL6081490 | 0.78 | MAPK14 (0.50) | MAPK14HTR7 | |
| SCHEMBL6081738 | 0.77 | MAPK14 (0.49) | MAPK14HTR7 | |
| SCHEMBL30123472 | 0.75 | MAPK14 (0.56) | MAPK14HTR7 | |
| SCHEMBL20187393 | 0.75 | MAPK14 (0.56) | MAPK14HTR7 | |
| SCHEMBL6081874 | 0.75 | MAPK14 (0.47) | MAPK14HTR7 | |
| SCHEMBL5814687 | 0.74 | KMT2A (0.76) | MAPK8MAPK9MAPK10KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060199821-A1 | Heterocyclic amides and sulfonamides | SCIOS, INC. (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199821-A1 | Heterocyclic amides and sulfonamides | MAP4K2, MAP3K8, MAP3K2 | MAPK8 6/4885MAPK9 38/4885MAPK10 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.